Speakers
Rob Hoeben
Dept of Cell and Chemical Biology, LUMC, Leiden
Rob Hoeben obtained his Master’s degree at Utrecht University with majors in Biology and Biochemistry in 1986. Then he moved to Leiden for his PhD research in the lab of Prof. Alex van der Eb to study the feasibility of gene therapy of hemophilia A. He obtained his PhD for his thesis ‘Towards gene therapy in haemophilia A: Vectors for the expression of blood‐clotting factor VIII in vivo’ at Leiden University in 1991. In his post-doctoral research he started working on adenovirus vectors for gene therapy and concentrated on their large scale production and their application in the field of cancer therapy. In 2000 he was appointed as full professor at Leiden University and the Leiden University Medical Center. Professor Hoeben has a long‐term interest in viruses and stem cells. His current research is focused on the development of oncolytic viruses and their application in cancer patients.
Stefan Braam
CEO Ncardia and Cellistic
Stefan Braam is the founder and CEO of Ncardia and Cellistic. Stefan brings Ncardia/Cellistic over a decade of experience in stem cell technology, product development and general management. Earlier in his career, Stefan obtained a MSc and PhD (both cum laude) in stem cell biology under supervision of Prof. Dr Mummery and obtained international experience in labs in the UK and Australia. Stefan won the NGI venture challenge (2009), the Niaba biobusiness Masterclass (2010), published in leading scientific journals, is an inventor on multiple patent families, secured several grants and technology licensing agreements and was with increasing responsibilities instrumental in Ncardia/Cellistic pre-seed, seed, Series A and B and C financing rounds.
Melissa van Pel
Head of Cell Therapy at NecstGen
Dr. Melissa van Pel is Head of Cell Therapy at NecstGen where she is responsible for process development and clinical manufacture for novel Cell and Gene Therapy products.
She obtained her PhD degree at the University of Utrecht in 2003. After an academic career focusing on molecular, cellular and functional aspects of hematopoietic and stromal cell populations, Melissa’s work shifted towards mesenchymal stromal cell (MSC) biology and the clinical applications of MSCs. Using pre-clinical animal models, she investigated the role of MSCs in several disease models, including atherosclerosis, lung emphysema, hematopoietic stem cell engraftment and colitis. Building upon this experience in MSC research, her research lines continued into Cell Therapy product development, optimisation of manufacturing processes, validation and additional product characterisation of Cell Therapy products according to GMP- and international standards.
As head of the Cell Therapy manufacture team in the Leiden University Medical Center, she was responsible for the expansion of MSCs for application in national and international clinical trials, ranging from phase I to III, including overseeing MSC manufacture in production centers in Germany and Spain.
Melissa has published over 40+ peer-reviewed scientific publications and participated in multiple national and international research consortia.
Martijn Kelder, Ph.D.
Sales Director at Cergentis
Martijn Kelder is a molecular geneticist with an academic background in genomics and genome editing. At Cergentis he heads the commercial and customer facing team. Martijn is a subject matter expert on the (regulatory requirements for) genetic characterisation of genome editing outcomes in cell therapy products and pharmaceutical cell lines. Martijn holds both BSc and MSc in molecular biology from Utrecht University and a Ph.D. in molecular genetics from University of Edinburgh and has published in leading journals including Nature, PLoS Biology and Genome Medicine.
Cor Marsman
QA Manager, QP and RP
Managing consultant
Progress
Cor started his career in 1982 as a medical analyst at the Gemini Hospital in Den Helder. In 1992 he graduated from the VU in Amsterdam as Biologist, with a major in Neurosciences. Since 1992 he has had several operational and quality management functions in very diverse companies related to the healthcare industry, including blood products, medical devices, biotech products, vaccines and advanced therapy products. During his career he has had QA responsibility for several large qualification and validation projects for upstream, downstream and fill-finish activities and at several locations he has been project manager for Quality Systems overhaul. As Quality manager/director (a.i.) Cor has been responsible for maintaining and improving Quality Systems and the performance of the QA officers team. He has been registered as a Qualified Person for different companies and also as Responsible Person.
Anja de Vries
Consultant
ATMP Quality expert
Anja started her career as a research analyst at Shell in 1975. Since 1999 she has build up for more as 20 years an extensive experience in implementation and managing of QMS systems in very diverse pharmaceutical companies. She has conducted several audits of contract manufacturing organizations - and testing organizations against the applicable regulatory GMP standards and customer expectations.
With her knowledge of the complex regulatory elements she has guided some successful inspections of regulatory bodies. She was part of the start-up of an Advanced Therapy Medicinal Products company first as consultant. For nearly 3 years she was Director QA responsible for the Quality System and Compliance of that company.
Frank van Engelenburg
CMC leader
Managing consultant
Progress
Frank is an experienced CMC Leader and has successfully led numerous CMC projects ranging from early development projects to late stage development and for MAA/BLA. In his role as CMC Leader he has been responsible for meeting quality aspects of different biologics, CMC development strategy, CMC regulatory strategy, and for CMC planning and budget control.
Frank holds a PhD in virology and was trained as a molecular biologist. After completing his PhD he worked as a Senior Scientist as Sanquin for 11 years and subsequently joined Kinesis-Pharma (Currently Venn) as Senior Consultant CMC for 10 years.
Regular ticket
access to the Dutch AMTP Summit at March 15th 2023.
299,- excl VAT
Dutch ATMP Summit 2023
With this ticket you will get access the the Dutch ATMP Summit on Wednesday March 15th 2023 in Amsterdam. You can join all the talks of our speakers and meet your colleagues in the field during networking drinks. During the day there are refreshments.
Second ticket for half of the price!
The fourth edition of the Dutch ATMP Summit will be held at
Wednesday March 12th 2025
Leave your contact details and we will update you on the program, speakers and early bird discount
About us
This summit is an initiative from Progress - Expert in Life Sciences
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We provide project management, interim management, temporary staffing and consultancy services in our expertise fields engineering & CQV, CMC &MSAT/ASAT and Quality (QA/QC/QP/RP)
About us
This summit is an initiative from Progress
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We operate internationally, project management, engineering & C&Q, CMC and Quality services.
Contact
Progress – Experts in Life Sciences
Bijlmermeerstraat 20
2131 HG Hoofddorp
+31 (0) 23 563 50 16
